CurrentCignaPolicy IP0393

Veregen

This Cigna coverage policy governs prior authorization and medical necessity criteria for prescription benefit coverage of Veregen (sinecatechins) ointment for external genital and perianal warts in adults, applying to Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyVeregen

Policy CodePolicy IP0393

Change TypeClarified titleno material criteria changes

Effective Date5/1/2026

Next Review Date5/1/2026

Key ActionSubmit prior authorization documenting age (≥18), immunocompetence, and failure/contraindication/intolerance to both podofilox and imiquimod.

SourceLink

POLICY UPDATE CHANGES

Updated coverage policy title from Sinecatechins to Veregen.

≥18minimum patient age for approval

4 monthsapproval duration

16 weekstreatment limit per labeling

2prior therapies required

Coverage Criteria

FDA-Approved Indication

Approve when ALL of the following are met:

FDA-Approved Indication: Patient has external genital or perianal warts (Condylomata acuminata)

based on FDA indication

Age: Patient is ≥ 18 years of age≥ 18 years

Immunocompetence: Patient is immunocompetent as indicated by the prescriber

Safety/efficacy not established in immunosuppressed patients

Prior therapy:

Policy Summary

PayerCigna

PolicyVeregen

Policy CodePolicy IP0393

Change TypeClarified titleno material criteria changes

Effective Date5/1/2026

Next Review Date5/1/2026

Key ActionSubmit prior authorization documenting age (≥18), immunocompetence, and failure/contraindication/intolerance to both podofilox and imiquimod.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions & Prior Authorization

Prior Authorization

Prior Authorization Required

Prior Authorization Required — approvals provided for 4 months when criteria met. Prescription benefit coverage of Veregen (sinecatechins) requires prior authorization. When the approval criteria are met (see step therapy and documentation requirements), authorizations are issued for a duration of 4 months.

Approval duration: 4 months
Applies to prescription benefit coverage of Veregen

Step Therapy

Step Therapy Requirement

Step therapy requirement — patient must have prior failure, contraindication, or intolerance to BOTH listed topical therapies before Veregen will be approved. Specifically, documentation must show trial of BOTH: 1) podofilox (gel or solution) AND 2) imiquimod (cream).

Required prior therapies: podofilox gel or solution AND imiquimod cream
Step requirement may be met by documented contraindication or intolerance to either agent

Documentation Required

Documentation Required for Prior Authorization

Required documentation for prior authorization. Providers must submit documentation that includes: patient age (≥ 18 years), prescriber assessment of immunocompetence, and evidence of prior therapies or documented contraindication/intolerance to BOTH podofilox and imiquimod. Include records of treatment attempts, dates, and reasons for discontinuation when applicable.

Age: patient ≥ 18 years
Immunocompetence: prescriber statement that patient is immunocompetent
Evidence of prior therapy: documentation of trial, failure, intolerance, or contraindication to podofilox (gel or solution) AND imiquimod (cream)
Receipt of sample product does not satisfy prior therapy requirements

Denial Risk

Prior Authorization and Indication Limits

Prior authorization and indication limits — claims submitted without an approved prior authorization or for indications other than FDA‑approved external genital or perianal warts in immunocompetent adults (with required prior therapies) will be denied as not medically necessary. Veregen for any other use is considered not medically necessary.

Covered indication: external genital or perianal warts in patients ≥ 18 years who are immunocompetent and meet step‑therapy requirements
Claims without prior authorization or for other indications will be denied
Authorizations issued only when all criteria are satisfied

Definitions

inv-10: External genital and perianal warts (Condylomata acuminata) — locations and management summary

DefinitionWarts located on the penis, groin, scrotum, vulva, perineum, external anus, or perianus (Condylomata acuminata) managed with patient- or provider-applied topical or procedural treatments.

FDA‑approved indicationTopical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients ≥ 18 years of age.

Key safety/efficacy limitsNot established in immunosuppressed patients, beyond 16 weeks of treatment, or for multiple treatment courses.

Typical clinical considerationsTreatment choice guided by wart size, number, location, patient preference, cost, convenience, adverse effects, and provider experience; most warts respond within ~3 months but may require reassessment if no response.

Alternative patient‑applied optionsImiquimod 3.7% or 5% cream and podofilox 0.5% solution or gel are CDC‑recommended patient-applied alternatives to Veregen.

OpenPayer

Veregen

Coverage Criteria

Coding

Provider Actions & Prior Authorization

Background

Definitions